{
  "docId": "019de076-91e2-76fd-b3d2-f30dde172711",
  "docSlug": "0239a71f9c69421092604a0a694fdb09",
  "documentTitle": "AstraZeneca | Investor Conference Presentation Deck | 26 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 26,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a horizontal layout to segment the business into five pillars, each with specific growth drivers and outlooks.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-91e2-76fd-b3d2-f30dde172711/4",
  "deckHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711",
  "deckJsonHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711.json",
  "deckAnchorHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.84,
        "x": 0.08,
        "y": 0.28
      },
      "kind": "image",
      "text": "Five circular icons representing Oncology, CVRM, R&I, V&I, and Rare Disease.",
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab7917a2-00f5-471e-ba56-933282fb984a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.18,
        "x": 0.42,
        "y": 0.54
      },
      "kind": "list",
      "text": "R&I: Strong growth through 2025 and beyond. Recent launch medicines offset Symbicort LoE",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3366d0d5-b6b2-4beb-970a-362e17590b76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.18,
        "x": 0.04,
        "y": 0.54
      },
      "kind": "list",
      "text": "Oncology: Consistent growth with LCM programmes and initial NME launches, including: Truqap, Dato-DXd and camizestrant",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "592f9ee3-0879-4f14-a529-ffa23f3b1297",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.18,
        "x": 0.61,
        "y": 0.54
      },
      "kind": "list",
      "text": "V&I: Emerging growth area, potential supported by Beyfortus, Icosavax (IVX-A12), Upside potential from COVID-19 mAb",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "791d7e63-b982-4208-a610-6611f1f4e3cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.18,
        "x": 0.23,
        "y": 0.54
      },
      "kind": "list",
      "text": "CVRM: Broadly stable to 2027, renewed growth from NME launches, including: dapagliflozin FDCs, baxdrostat, Wainua",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "870e99e0-0467-4dbe-9c80-e187348f05da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.18,
        "x": 0.8,
        "y": 0.54
      },
      "kind": "list",
      "text": "Rare Disease: Continued Complement leadership from Neurology and new indications. Successful diversification with next-gen HPP and amyloidosis portfolio",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b854c085-2c79-4687-a236-4bb12e803a9b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.04,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "1. Icosavax acquisition remains subject to customary external closing conditions; all clinical development plans mentioned herein subject to deal closure. Collaboration partners: Daiichi Sankyo (Dato-Dxd), Sanofi (Beyfortus), Ionis (Wainua).",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b4fc37a-1b5c-46a7-b4d6-922dd5491a23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.9,
        "x": 0.05,
        "y": 0.84
      },
      "kind": "title",
      "text": "Growth through 2030 supported by existing portfolio, innovative LCM and initial NME launches",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d9868c3-5422-4721-ae1a-a98c423536b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.75,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "AstraZeneca – industry-leading growth through 2030",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afd810dd-d4f7-4ed8-82cb-5ef2187ad7bd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "73552993-96e2-447a-9134-bea0cec5ad41",
      "evidence": "list/bullet: Rare Disease: Continued Complement leadership from Neurology and new indications. Successful diversification with next-gen HPP and amyloidosis portfolio",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 4,
      "beatId": "89e38b66-4827-4196-94f1-792b29dc13ee",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Early Struggles",
      "beatSlug": "rags-to-riches-early-struggles",
      "evidence": "The deck highlights AstraZeneca's growth challenges and opportunities.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 4,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "4e7501eb-74e6-4ae7-8a18-04c13b6f5ddc",
      "evidence": "The deck outlines AstraZeneca's growth strategy and supporting data.",
      "position": 0,
      "objective": "How AstraZeneca's growth strategy will drive growth through 2030",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}